MRC1 and cancer: In contrast with these previous reports, we found that low doses of MMR can infect and lyse murine HCC cells in vitro, suggesting that the in vivo anti-cancer activity of MMR is multimodal via potential induction of cytolytic cell death and activation of immune responses within the tumor which led to tumor regression and extended survival in the model studied (51–54, 126).